Patents by Inventor Kobi ROSENBLUM

Kobi ROSENBLUM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR DELIVERY AND EXPRESSION OF SMALL INHIBITORY PEPTIDES AND USE THEREOF
    Publication number: 20210079050
    Abstract: The present invention is directed to, inter alia, a chimeric polynucleotide made up of a first polynucleotide encoding a specific cell predominantly expressed protein precursor and a second polynucleotide encoding a modulating-peptide. Further provided are methods for specific delivery of small modulating peptides to specific cells. Also provided are methods for treating cell-specific-associated diseases, including but not limited to, muscular, neural, hepatic and pancreatic disease, in a subject in need thereof.
    Type: Application
    Filed: February 20, 2019
    Publication date: March 18, 2021
    Inventors: Kobi ROSENBLUM, Efrat EDRY
  • Methods for improving cognitive function via modulation of quinone reductase 2
    Patent number: 10676747
    Abstract: An active agent capable of reducing quinone reductase 2 activity is for use in improvement of cognition in a subject. Such an active agent can be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A pharmaceutical composition can contain the active agent or a vector containing the active agent.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: June 9, 2020
    Assignee: CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD.
    Inventors: Kobi Rosenblum, Akiva Rappaport
  • METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2
    Publication number: 20190119684
    Abstract: An active agent capable of reducing quinone reductase 2 activity is for use in improvement of cognition in a subject. Such an active agent can be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A pharmaceutical composition can contain the active agent or a vector containing the active agent.
    Type: Application
    Filed: October 29, 2018
    Publication date: April 25, 2019
    Inventors: Kobi ROSENBLUM, Akiva RAPPAPORT
  • Genetic or pharmacological reduction of PERK enhances cortical- and hippocampus-dependent cognitive function
    Patent number: 10246712
    Abstract: A method for improving a cognitive function in a subject comprising administering to said subject an active agent reducing PKR-like endoplasmic reticulum kinase (PERK) activity is provided.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: April 2, 2019
    Assignee: Carmel-Haifa University Economic Corp. Ltd.
    Inventors: Kobi Rosenblum, Vijendra Sharma, Hadile Ounallah Saad
  • Methods for improving cognitive function via modulation of quinone reductase 2
    Patent number: 10113171
    Abstract: An active agent capable of reducing quinone reductase 2 activity, for use in improvement of cognition in a subject is provided. Such an active agent may be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A vector comprising a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 and a pharmaceutical composition comprising an active agent capable of reducing quinone reductase 2 activity or said vector are provided as well.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: October 30, 2018
    Assignee: Carmel-Haifa University Economic Corp. Ltd.
    Inventors: Kobi Rosenblum, Akiva Rappaport
  • Genetic Or Pharmacological Reduction Of Perk Enhances Cortical- And Hippocampus-Dependent Cognitive Function
    Publication number: 20180265873
    Abstract: A method for improving a cognitive function in a subject comprising administering to said subject an active agent reducing PKR-like endoplasmic reticulum kinase (PERK) activity is provided.
    Type: Application
    Filed: October 27, 2016
    Publication date: September 20, 2018
    Inventors: Kobi ROSENBLUM, Vijendra SHARMA, Hadile OUNALLAH SAAD
  • Methods for improving cognitive function via modulation of quinone reductase 2
    Publication number: 20170081669
    Abstract: An active agent capable of reducing quinone reductase 2 activity, for use in improvement of cognition in a subject is provided. Such an active agent may be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A vector comprising a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 and a pharmaceutical composition comprising an active agent capable of reducing quinone reductase 2 activity or said vector are provided as well.
    Type: Application
    Filed: March 18, 2015
    Publication date: March 23, 2017
    Inventors: Kobi ROSENBLUM, Akiva RAPPAPORT